The guidelines provide a comprehensive framework for the management of inflammatory bowel disease (IBD) in adults, covering both ulcerative colitis (UC) and Crohn's disease (CD). They are intended to standardize clinical practice in the United Kingdom, emphasizing the importance of individualized care based on patient preferences and clinical data. The guidelines are based on a thorough literature review and expert consensus, with recommendations graded according to the quality of evidence. The impact of IBD on patients and society is significant, affecting quality of life, employment, and psychological well-being. The guidelines emphasize the need for rapid access to care, multidisciplinary teams, and comprehensive patient support. They also highlight the importance of audit and feedback to improve service delivery. The clinical features, diagnosis, and treatment of UC and CD are detailed, including the use of aminosalicylates, corticosteroids, thiopurines, methotrexate, cyclosporin, and biological agents like infliximab. The guidelines provide specific recommendations for the management of active and severe disease, maintenance of remission, and the role of surgical intervention. For UC, the guidelines recommend aminosalicylates or corticosteroids for active disease, with lifelong maintenance therapy to reduce the risk of relapse and colorectal cancer. For CD, the guidelines suggest a similar approach but with additional considerations for the site and pattern of disease. The guidelines also address the challenges of managing complex cases and the need for ongoing research to improve treatment options.The guidelines provide a comprehensive framework for the management of inflammatory bowel disease (IBD) in adults, covering both ulcerative colitis (UC) and Crohn's disease (CD). They are intended to standardize clinical practice in the United Kingdom, emphasizing the importance of individualized care based on patient preferences and clinical data. The guidelines are based on a thorough literature review and expert consensus, with recommendations graded according to the quality of evidence. The impact of IBD on patients and society is significant, affecting quality of life, employment, and psychological well-being. The guidelines emphasize the need for rapid access to care, multidisciplinary teams, and comprehensive patient support. They also highlight the importance of audit and feedback to improve service delivery. The clinical features, diagnosis, and treatment of UC and CD are detailed, including the use of aminosalicylates, corticosteroids, thiopurines, methotrexate, cyclosporin, and biological agents like infliximab. The guidelines provide specific recommendations for the management of active and severe disease, maintenance of remission, and the role of surgical intervention. For UC, the guidelines recommend aminosalicylates or corticosteroids for active disease, with lifelong maintenance therapy to reduce the risk of relapse and colorectal cancer. For CD, the guidelines suggest a similar approach but with additional considerations for the site and pattern of disease. The guidelines also address the challenges of managing complex cases and the need for ongoing research to improve treatment options.